A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Sponsor

Amgen (Industry)

Overall Status

Completed

CT.gov ID

NCT01331941

Collaborator

(none)

Enrollment

Locations

Arms

8.8

Patients Per Site

Study Details

Study Description

Brief Summary

This is a phase 1, open-label pharmacokinetic study where up to 40 subjects with advanced solid tumors (up to 6-10 with normal renal function and up to 18-30 with varying degrees of renal dysfunction) will receive weekly doses of AMG 386 intravenously. The primary objective is to evaluate the pharmacokinetics (PK) of single agent AMG 386 in subjects with various degrees of renal function. Once the AMG 386 PK characterization is complete in the first 5 weeks of the study, all subjects will be allowed to continue to receive AMG 386 weekly only or subjects in group 1, 2 or 3 can opt to receive AMG 386 weekly in combination with paclitaxel until disease progression, unacceptable toxicity or withdrawal of consent.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumors Kidney Disease Renal Impairment	Drug: AMG 386 + Paclitaxel Drug: AMG 386	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

35 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function

Actual Study Start Date :

Sep 19, 2011

Actual Primary Completion Date :

Feb 26, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1 Cancer subjects with normal renal function.	Drug: AMG 386 + Paclitaxel 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent. Drug: AMG 386 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
Experimental: Group 3 Cancer subjects with moderate renal impairment.	Drug: AMG 386 + Paclitaxel 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent. Drug: AMG 386 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
Experimental: Group 4 Cancer subjects with severe renal impairment.	Drug: AMG 386 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
Experimental: Group 2 Cancer subjects with mild renal impairment.	Drug: AMG 386 + Paclitaxel 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent. Drug: AMG 386 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.

Outcome Measures

Primary Outcome Measures

Area under the serum concentration-time curve (AUC) [Week 1-5.]
Maximum observed concentration (Cmax) [Week 1-5.]
Time to maximum concentration (tmax) [Week 1-5.]
Minimum observed concentration (Cmin) [Week 1-5.]
Clearance (CL) of AMG 386 calculated as dose divided by AUC on week 5. [Week 1-5]

Secondary Outcome Measures

Adverse events as a measure of safety [Weekly at each visit AMG 386 is administered, on day 30, 31 and 32 when only PK assessments are scheduled up to and including the last study visit 30 days after the last AMG 386 administration.]
Changes in vital signs as a measure of safety [Weekly at each visit AMG 386 is administered up to and including the last study visit 30 days after the last AMG 386 administration.]
Changes in clinical laboratory tests as a measure of safety [Weekly from week 1-9 then every 4 weeks thereafter including the last study visit 30 days after the last AMG 386 administration.]
Anti-AMG 386 antibody formation [Week 1, week 5, week 9 and every 16 weeks thereafter including the last study visit 30 days after the last AMG 386 administration.]
Tumor objective response measured by CT or MRI (without Gadolinium contrast agents) and assessed by RECIST 1.1 criteria. [Week 5 and every 8 weeks thereafter until the subject's end of participation in the study.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Men or women ≥ 18 years of age
Must have a pathologically documented, and definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy
Evaluable OR measurable disease by RECIST 1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Life expectancy of > 3 months, in the opinion of and as documented by the investigator
Subject or subject's legally acceptable representative has provided informed consent

Exclusion Criteria:

Subjects with gastric cancer or any malignancy with purely squamous cell histology
Known history of primary central nervous system (CNS) tumors or CNS metastases
Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association > class II, uncontrolled hypertension [diastolic > 90 mmHg; systolic > 150 mmHg in repeated measurements])
History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1
Active grade 2 or greater peripheral vascular disease or peripheral edema
History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
Non-healing wound, ulcer (including gastrointestinal) or fracture
Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection
Major surgery within 4 weeks before study day 1
Absolute neutrophils count (ANC) < 1.0 x 10^{9/L; or platelet count < 100 x 10}9/L; or hemoglobin < 9 g/dL; or PTT / aPTT > 1.5 x institutional upper limit of normal (ULN) ); or INR > 1.5
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN (> 5.0 x ULN if liver metastases present)
Alkaline phosphatase > 2.5 x ULN (> 5.0 x ULN if attributable to liver or bone metastasis)
Total bilirubin > 1.5 x ULN
Other investigational procedures during the study
Previous anti-cancer therapy or investigational agent within 4 weeks prior to study day 1
Anticoagulation therapy within 4 weeks of study day 1 and while on study (except low dose warfarin (≤ 2 mg/kg) for prophylaxis against central venous catheter thrombosis)
Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women).
Women who are lactating/breastfeeding.
Women with a positive pregnancy test.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Atlanta	Georgia	United States	30332
2	Research Site	Chicago	Illinois	United States	60637
3	Research Site	Lebanon	New Hampshire	United States	03756
4	Research Site	Cleveland	Ohio	United States	44106